AI is accelerating health and medical research; personalised medicine is now a reality and new treatments are pushing the boundaries of what medicine can achieve, but a major question remains: whether they can prove, manufacture, finance and safely deliver them at scale?
The new 34-page research report “Beyond 2030: The Future of Life Sciences” released by Zurich Insurance Group (Zurich) in October 2026, says that the industry's biggest challenges increasingly arise after discovery. The question is no longer only whether companies can develop breakthroughs, but whether they can prove, manufacture, finance and safely deliver them at scale.
A media release by Zurich said, “Drawing on interviews with industry experts and a survey of specialists, the report reveals that success in the next decade will depend as much on the systems surrounding innovation as on the science itself. Manufacturing capacity, trusted data, regulatory pathways, financing models and resilient partnerships are becoming critical factors in determining whether breakthrough innovations ultimately reach patients.”
Zurich Insurance Group Chief Underwriting Officer International Penny Seach said, “Innovation in life sciences is accelerating, but so are the risks and complexities surrounding it. The companies that succeed will be those that can identify critical dependencies, build resilience and navigate the regulatory, technological and operational challenges that stand between discovery and delivery.”
The report identifies four interconnected trends that are likely to reshape the industry over the next decade.
1) National security is shaping innovation
Governments increasingly see manufacturing, health data and critical technologies as strategic assets. As trade policies and geopolitical tensions reshape access to these capabilities, where innovation happens and who can participate are becoming strategic questions, not just scientific ones.
2) Discovery is faster, but proving what works remains slow
AI is accelerating discovery, but scientific progress is only the beginning. Clinical evidence, regulatory approval, manufacturing and reimbursement are the factors that determine whether innovation reaches patients.
3) Care is moving beyond traditional institutions
Healthcare is increasingly delivered through connected devices, digital platforms and patient-managed tools. This creates new opportunities for patients, while raising important questions around accountability, cybersecurity and data governance.
4) One-time treatments require new business models
More therapies are delivering long-term benefits from a single intervention rather than ongoing treatment. While this has the potential to improve outcomes, it is forcing healthcare systems and companies to rethink how innovation is financed, priced and rewarded.
Together, these trends point to a broader change: Competitive advantage is increasingly moving beyond the product itself. Companies will need to think earlier about the factors that determine whether an innovation reaches patients, from regulation and market access to pricing and reimbursement. They will also need to secure critical capabilities such as manufacturing, data and technology, while building accountability for decisions, data and outcomes into products from the outset.
The report concludes that life sciences enter the 2030s with extraordinary scientific momentum. However, the organizations best positioned to succeed may not be those that make the most breakthroughs, but those that can reliably scale, finance, govern and deliver them.